Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate
International Clinical Psychopharmacology, 08/10/2012
Sheehan DV et al. – Quetiapine XR (50–300mg/day) monotherapy better maintains overall functioning and sleep quality than placebo in patients with major depressive disorder.Methods
- A double-blind, randomized-withdrawal maintenance study of quetiapine XR monotherapy was carried out in patients with major depressive disorder.
- Following 4–8weeks of open-label quetiapine XR and 12–18weeks of open-label quetiapine XR stabilization (50, 150, or 300mg/day), eligible patients were randomized to quetiapine XR (50, 150, or 300mg/day) or placebo.
- Secondary variables of the Sheehan Disability Scale (SDS) and the Pittsburgh Sleep Quality Index (PSQI) were used to assess functioning and sleep quality and are reported here.
- Quetiapine XR significantly maintained functioning versus placebo.
- Changes in the least squares means (LSM) from randomization in the SDS total scores were as follows:-0.45, quetiapine XR (P<0.05), versus 0.44, placebo.
- Quetiapine XR significantly maintained SDS domains ‘social life/leisure’ (-0.19; P<0.05) and ‘family life/home responsibilities’ (-0.22; P<0.05) versus placebo (0.13 and 0.10, respectively).
- Quetiapine XR significantly maintained sleep quality (LSM change in PSQI total scores: 0.06, quetiapine XR vs. 1.35, placebo; P<0.001), with five of seven PSQI components being significant for quetiapine XR versus placebo.